Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 2;33(1):17-25.
doi: 10.1515/jbcpp-2020-0495.

A new application of mTOR inhibitor drugs as potential therapeutic agents for COVID-19

Habibeh Mashayekhi-Sardoo  1 , Hesamoddin Hosseinjani  2
Affiliations
Free article
Review

A new application of mTOR inhibitor drugs as potential therapeutic agents for COVID-19

Habibeh Mashayekhi-Sardoo et al. J Basic Clin Physiol Pharmacol. .
Free article

Abstract

Since December 2019, the COVID-19 emerging pandemic caused by SARS-CoV-2 has resulted in one of the most important global health threats. Concerning the absence of an approved effective vaccine or drug for the treatment and outcome improvement of COVID-19 patients, and the role of SARS-CoV-2 in activation of mammalian target of rapamycin (mTOR) pathway, we decided to review the previous data regarding the therapeutic effect of mTOR inhibitor drugs in COVID-19 patients. We searched the scientific databases such as Web of Science, Embase, Medline (PubMed), Scopus, and Google Scholar using appropriate keywords to find suitable studies or suggestions until October 2020. The findings of the current study confirmed that mTOR inhibitor drugs through suggested mechanisms such as T cell adjustment, induction of autophagy without apoptosis, reduction of viral replication, restoration of the T-cell function, decrease cytokine storm, and moderation of the mTOR-PI3K-AKT pathway activation bring about a therapeutic impact in COVID-19 patients. Taken together, it is necessary to find a suitable therapy for the COVID-19 pandemic emerging. In this regard, we clarify that it is valuable to consider the therapeutic effect of mTOR inhibitor drugs and metformin by its mTOR inhibition property in the treatment of COVID-19 patients.

Keywords: COVID-19; SARS-CoV-2; coronavirus; mTOR inhibitors; metformin; rapamycin; sirolimus.

PubMed Disclaimer

References

    1. Fauci, AS, Lane, HC, Redfield, RR. Covid-19—navigating the uncharted. Mass Medical Soc 2020;382:1268–9. https://doi.org/10.1056/NEJMe2002387.
    1. Ackermann, M, Verleden, SE, Kuehnel, M, Haverich, A, Welte, T, Laenger, F, et al.. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020;383:120–8. https://doi.org/10.1056/NEJMoa2015432.
    1. Tyrrell DA, Bynoe ML. Cultivation of a novel type of common-cold virus in organ cultures. Br Med J 1965;1:1467–70. https://doi.org/10.1136/bmj.1.5448.1467.
    1. Catharine, I, Paules, HDM, Fauci, AS. Coronavirus infections—more than just the common cold. J Am Med Assoc 2020;323:707–8. https://doi.org/10.1001/jama.2020.0757.
    1. Rameshrad, M, Ghafoori, M, Mohammadpour, AH, Nayeri, MJD, Hosseinzadeh, H. A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19). N Schmied Arch Pharmacol 2020;393:1137–52. https://doi.org/10.1007/s00210-020-01901-6.

MeSH terms

LinkOut - more resources